SUPPLEMENAL MATERIALS

Supplemental file 1. Assay performance

Performance of the assays during study conduct was measured using quality control samples (QCs) prepared in a blank matrix containing analytes of interest. Verinurad human plasma QCs showed an accuracy (measured by %Relative Error, %RE) between –9.3 and 0.0%, while the precision of the QCs (measured by %Coefficient of Variation, %CV) was ≤7.3%. Allopurinol plasma QCs demonstrated %RE and %CV values of –4.0 to 1.0% and ≤6.1% and oxypurinol plasma QCs demonstrated %RE and %CV values of –8.0 to –0.3% and ≤7.7%, respectively. Verinurad human urine QCs showed %RE values of –1.9 to 2.0%, while the %CV was ≤4.1%. Allopurinol urine QCs demonstrated %RE and %CV values of –5.3 to 0.0% and ≤6.1 and oxypurinol urine QCs demonstrated %RE and %CV values of –5.6 to -2.0% and ≤7.0%, respectively.

Supplemental Figure 1 Mean (SE) plasma concentration profiles of verinurad (ng/mL) following once-daily oral administration of varying verinurad doses in combination with allopurinol 300 mg (Cohort 1 and Cohort 2).

